Volume 2.22 | Jun 7

Hematopoiesis News 2.22, June 7, 2011
     In this issue: Science News | Current Publications | Industry News | Policy News | Events
Cell Therapy News on Facebook  Hematopoiesis News on Twitter

Hierarchical Organization and Early Hematopoietic Specification of the Developing HSC Lineage in the AGM Region
Scientists developed a new co-aggregation culture system, which supports maturation of a novel population of CD45-negative (VE-cad+CD45CD41+) pre-hematopoietic stem cells (HSCs) into definitive HSCs. [J Exp Med]



Stem Cell Treatment to Prevent Leukemia Returning Is a Step Closer
Researchers have identified a way of eliminating leukemic stem cells, which could in the future lead to new treatments that may enable complete remission for leukemia patients. [Press release from King’s College London discussing online prepublication in Cell Stem Cell]

Scientists Sequence the Genome for Chronic Lymphocytic Leukemia
A team of Spanish scientists has sequenced the complete genomes of healthy and tumor cells from patients with chronic lymphocytic leukemia. [Press release from the Institute for Research in Biomedicine Barcelona discussing online prepublication in Nature]

Wake Forest Baptist Medical Center and Cornerstone Pharmaceuticals Present Interim Data from Phase I Trial of CPI-613 in Acute Myeloid Leukemia
Cornerstone Pharmaceuticals and Wake Forest Baptist Medical Center announced key findings from a Phase I clinical trial of Cornerstone’s first in-class cancer metabolism inhibitor drug, CPI-613 in acute myeloid leukemia. [Press release from Cornerstone Pharmaceuticals discussing research presented at the 47th Annual Meeting of the American Society of Clinical Oncology]

Talon Therapeutics Presents Marqibo® Hematopoietic Stem Cell Transplantation “Bridging” Data at American Society of Clinical Oncology 2011 Annual Meeting
Talon Therapeutics, Inc. presented a poster titled “VSLI (vincristine sulfate liposomes injection, Marqibo) “Bridging” to Potentially Curative Hematopoietic Stem Cell Transplantation in Adults with Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia”. [Press release from Talon Therapeutics discussing research presented at the 47th Annual Meeting of the American Society of Clinical Oncology]


CURRENT PUBLICATIONS (Ranked by Impact Factor of the Journal)


Whole-Genome Sequencing Identifies Recurrent Mutations in Chronic Lymphocytic Leukemia
Scientists performed whole-genome sequencing of four cases of chronic lymphocytic leukemia and identified 46 somatic mutations that potentially affect gene function. [Nature]

Functional Crosstalk Between Bmi1 and MLL/Hoxa9 Axis in Establishment of Normal Hematopoietic and Leukemic Stem Cells
In this study, researchers investigated whether leukemia-associated fusion proteins could initiate leukemia in the absence of Bmi1. [Cell Stem Cell]

Wnt-Inhibitory Factor 1 Dysregulation of the Bone Marrow Niche Exhausts Hematopoietic Stem Cells
Investigators reported that osteoblastic Wnt inhibitory factor 1 over-expression disrupts stem cell quiescence leading to a loss of self-renewal potential. [Blood]

Il-7 Mediates Ebf-1–Dependent Lineage Restriction in Early Lymphoid Progenitors
In order to understand more about how Il-7 deficiency impacts early lymphoid development, scientists have investigated lineage restriction events within the common lymphoid progenitor compartment in Il-7 knockout mice. [Blood]

Irgm1 Protects Hematopoietic Stem Cells by Negative Regulation of Interferon Signaling
To investigate the molecular basis for these defects, researchers conducted microarray expression profiling of Irgm1-deficient hematopoietic stem cells. [Blood]

FLT3 Expression Initiates in Fully Multipotent Mouse Hematopoietic Progenitor Cells
Investigators demonstrated that mouse Flt3 expression initiates in fully multipotent progenitors, as not only lymphoid and granulocyte-monocyte progenitors, but also FLT3 Mk and E restricted downstream progenitors are highly labeled when applying Flt3-Cre fate mapping. [Blood]

Neurexophilin 1 Suppresses the Proliferation of Hematopoietic Progenitor Cells
Results demonstrate the presence and function of a regulated signaling axis in hematopoiesis centered on Neurexin I α and its modulation by dystroglycan and neurexophilin 1. [Blood]

Mechanisms of Cytotoxicity to Pim Kinase Inhibitor, SGI-1776, in Acute Myeloid Leukemia
Pim are ser/thr kinases with multiple substrates that affect survival pathways. These proteins are overexpressed in acute myeloid leukemia (AML) blasts and scientists hypothesized that Pim kinase inhibition would affect AML cell survival. [Blood]

MiR-17/20/93/106 Promote Hematopoietic Cell Expansion by Targeting Sequestosome 1-Regulated Pathways in Mice
Researchers show that ectopic expression of miR-17,-20,-93 and -106 increases proliferation, colony outgrowth and replating capacity of myeloid progenitors and results in enhanced P-ERK levels. [Blood]

MiR-100 Regulates Cell Differentiation and Survival by Targeting RBSP3, a Phosphatase-Like Tumor Suppressor in Acute Myeloid Leukemia
Data highlights an important role of microRNA-100 (miR-100) in the molecular etiology of acute myeloblastic leukemia, and implicate the potential application of miR-100 in cancer therapy. [Oncogene]


Long-Term Health-Related Outcomes in Survivors of Childhood Cancer Treated with Hematopoietic Cell Transplantation (HCT) Versus Conventional Therapy: A Report from the Bone Marrow Transplant Survivor Study  and Childhood Cancer Survivor Study
Scientists compared the risk of chronic health conditions and adverse health among children with cancer treated with HCT, with survivors treated conventionally, as well as with sibling controls. [Blood]

Influence of Immunosuppressive Treatment on Risk of Recurrent Malignancy after Allogeneic Hematopoietic Cell Transplantation
This study was conducted to elucidate the influence of immunosuppressive treatment and graft-versus-host disease on risk of recurrent malignancy after allogeneic hematopoietic cell transplantation. [Blood]

IDH1 and IDH2 Mutations in Pediatric Acute Leukemia
To investigate the frequency of isocitrate dehydrogenase 1 (IDH1) and 2 (IDH2) mutations in pediatric acute myeloid leukemia (AML) and acute lymphoid leukemia (ALL), investigators sequenced these genes in diagnostic samples from 515 patients (227 AMLs and 288 ALLs). [Leukemia]


SymBio Announces Korea NDA Approval of Bendamustine Hydrochloride (SyB L-0501)
SymBio Pharmaceuticals Limited announced that the Korea Food and Drug Administration approved bendamustine HCI (SyB L-0501) for the treatment of patients with chronic lymphocytic leukemia and multiple myeloma on May 31, 2011. [SymBio Pharmaceuticals Limited Press Release]

European Commission Adopts European Medicines Agency’s (EMA) Recommendation to Lift the Suspension of the Marketing Authorization of Octagam® and Octagam®10%
The European Commission adopted the EMA’s recommendation to lift the suspension of the marketing authorization of octagam® and octagam®10%, thus allowing both products back on the European markets. [Octapharma AG Press Release]

Medco Partners with MolecularMD on Personalized Medicine Program for Chronic Myeloid Leukemia
Medco Health Solutions, Inc. and MolecularMD Corp. announced the launch of a personalized medicine program for chronic myeloid leukemia (CML) patients. Through this program, Medco will offer patients diagnosed with CML quantitative real-time polymerase chain reaction BCR-ABL to monitor the disease. [Medco Health Solutions, Inc. Press Release]

Cells Do Talk to One Another, but the Question Remains How
The National Science Foundation’s Advances in Biological Informatics program area has awarded a three-year, $1.12 million research grant to three Virginia Tech researchers with expertise in systems biology and tissue engineering. [Virginia Tech Press Release]


National Institutes of Health (United States)

Food and Drug Administration (United States)
Center for Biologics Evaluation and Research (United States)
European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)


NEW Screening Stem Cells 2011: From Reprogramming to Regenerative Medicine
September 26-27, 2011
Boston, United States

Visit our events page to see a complete list of events in the hematopoietic community

Chemist (STEMCELL Technologies)

Research and Development Senior Technologist (STEMCELL Technologies)

Postdoctoral Associate (University of Massachusetts Medical School)

Post Doctoral Fellow (MedImmune)

Laboratory Project Scientist (University of California, San Diego)

Postdoctoral Fellow (Indiana University) 

Early Stage Researcher Marie Curie Fellowship in Cancer Stem Cell Research (University Medical Center Groningen) 

Recruit Top Talent

Reach more than 11,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Jobs are categorized regionally: United States, Canada, Europe, Asia Pacific

Visit here to post your career opportunities.

Have we missed an important article or publication in Hematopoiesis News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Hematopoiesis Cell News: Archives | Events | Contact Us